Treatment with Cosentyx (secukinumab) continues to be safe and to ease symptoms in people with active ankylosing spondylitis (AS) through three years of use, new data from a Phase 3 trial show. The three-year data were reported in a study, titled “Secukinumab 150/300…
People with ankylosing spondylitis (AS) have an altered composition of microorganisms in their gut, leading to more bacteria that play a role in inflammation and AS progression, a new study reports. The study, “Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis,” was published in the…
Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA). The medication is used to treat nr-axSpA patients with evidence of active inflammation, as indicated by magnetic resonance imaging and/or levels of the blood marker C-reactive…
Qletli, a biosimilar to Humira (adalimumab), is now available in China for the treatment of three autoimmune diseases, including ankylosing spondylitis (AS). The medication is also approved for the treatment of rheumatoid arthritis and plaque psoriasis. With its approval by China’s National Medical Products Administration (NMPA)…
Analyzing the levels of a protein called DNASE1L3 may enable an accurate diagnosis of ankylosing spondylitis (AS), a study suggests. Besides being able to distinguish between AS and generalized osteoarthritis, this potential biomarker may also differentiate between active and inactive AS disease. The study, “Serum Deoxyribonuclease…
Mabpharm has filed an application with China’s National Medical Products Administration (NMPA) seeking approval of a biobetter of infliximab, a biological treatment for people with ankylosing spondylitis and other inflammatory disorders. Sorrento Therapeutics, the company owning global rights to the biobetter antibody outside of China,…
Despite experiencing similar symptoms, people with non-radiographic axial spondyloarthritis (nr-axSpA) are less likely to be treated with a biologic therapy than those with ankylosing spondylitis (AS), according to a survey in the U.S. The research was presented in a session, “Comparing Symptoms, Treatments Patterns, and Quality of…
The first ankylosing spondylitis (AS) patient has been dosed in a Phase 3 trial testing SCB-808, a potential biosimilar of Enbrel (etanercept) being developed for the treatment of rheumatic diseases in China. Biosimilars are biological medical products highly similar to a reference product. They are manufactured by…
The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated due to inflammation when treatment is started, new research suggests. The findings were presented in a session, titled “Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients…
Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were discussed at the 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in a presentation, titled…
Get regular updates to your inbox.